HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Cecilia Sgadari Selected Research

Kaposi Sarcoma (Kaposi's Sarcoma)

2/2022Kaposi's Sarcoma Lesion Progression in BKV-Tat Transgenic Mice Is Increased by Inflammatory Cytokines and Blocked by Treatment with Anti-Tat Antibodies.
1/2011Fibroblast Growth Factor-2 and the HIV-1 Tat Protein Synergize in Promoting Bcl-2 Expression and Preventing Endothelial Cell Apoptosis: Implications for the Pathogenesis of AIDS-Associated Kaposi's Sarcoma.
2/2009Clinical course of classic Kaposi's sarcoma in HIV-negative patients treated with the HIV protease inhibitor indinavir.
4/2006HIV-1 Tat regulates endothelial cell cycle progression via activation of the Ras/ERK MAPK signaling pathway.
9/2003Use of HIV protease inhibitors to block Kaposi's sarcoma and tumour growth.
8/2003HIV protease inhibitors as new treatment options for Kaposi's sarcoma.
2/2003[HIV protease inhibitors for the treatment of Kaposi's sarcoma].
3/2002HIV protease inhibitors are potent anti-angiogenic molecules and promote regression of Kaposi sarcoma.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Cecilia Sgadari Research Topics

Disease

8Neoplasms (Cancer)
02/2022 - 11/2002
8Kaposi Sarcoma (Kaposi's Sarcoma)
02/2022 - 03/2002
8Disease Progression
08/2019 - 02/2009
6Infections
08/2019 - 11/2002
5Acquired Immunodeficiency Syndrome (AIDS)
02/2022 - 11/2002
2Carcinoma (Carcinomatosis)
12/2020 - 05/2017
2Uterine Cervical Dysplasia
12/2020 - 05/2017
2Viremia
01/2019 - 04/2015
1HIV Infections (HIV Infection)
12/2020
1Asymptomatic Diseases
06/2016
1Adenocarcinoma
01/2011
1Lymphoma (Lymphomas)
09/2003
1Inflammation (Inflammations)
09/2003
1Neoplasm Metastasis (Metastasis)
09/2003

Drug/Important Bio-Agent (IBA)

11HIV Protease InhibitorsIBA
12/2020 - 03/2002
5CytokinesIBA
02/2022 - 11/2002
5Indinavir (Crixivan)FDA Link
12/2020 - 08/2003
5Saquinavir (Invirase)FDA Link
12/2020 - 08/2003
4AntibodiesIBA
02/2022 - 06/2014
4Matrix Metalloproteinases (MMPs)IBA
12/2020 - 01/2011
3VaccinesIBA
02/2022 - 01/2009
3Ritonavir (Norvir)FDA Link
12/2020 - 09/2003
2tat Gene Products (tat Protein)IBA
02/2022 - 01/2011
2Virulence Factors (Pathogenicity Factors)IBA
01/2015 - 06/2014
2Trans-Activators (Trans-Acting Factor)IBA
01/2015 - 04/2006
2IntegrinsIBA
06/2014 - 01/2012
2Angiogenesis Inducing Agents (Angiogenesis Factor)IBA
08/2011 - 11/2002
2Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor)IBA
01/2011 - 02/2009
2Protease Inhibitors (Protease Inhibitor)IBA
01/2011 - 09/2003
2Pharmaceutical PreparationsIBA
02/2009 - 02/2003
1LopinavirFDA Link
12/2020
1Estrogens (Estrogen)FDA Link
12/2020
1Tissue Inhibitor of Metalloproteinase-3IBA
12/2020
1Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
12/2020
1DNA (Deoxyribonucleic Acid)IBA
01/2019
1Proteins (Proteins, Gene)FDA Link
05/2018
1Peptide Hydrolases (Proteases)FDA Link
05/2018
1Matrix Metalloproteinase 14 (MT1-MMP)IBA
10/2014
1Proteasome Endopeptidase Complex (Proteasome)IBA
01/2011
1Biomarkers (Surrogate Marker)IBA
02/2009
1Nelfinavir (Viracept)FDA Link
09/2003
1EnzymesIBA
02/2003
1Human immunodeficiency virus 1 p16 proteaseIBA
03/2002

Therapy/Procedure

7Therapeutics
02/2022 - 11/2002
3Highly Active Antiretroviral Therapy (HAART)
08/2019 - 09/2003